AU2001296821A1 - Methods of inhibiting angiogenesis using nadph oxidase inhibitors - Google Patents

Methods of inhibiting angiogenesis using nadph oxidase inhibitors

Info

Publication number
AU2001296821A1
AU2001296821A1 AU2001296821A AU9682101A AU2001296821A1 AU 2001296821 A1 AU2001296821 A1 AU 2001296821A1 AU 2001296821 A AU2001296821 A AU 2001296821A AU 9682101 A AU9682101 A AU 9682101A AU 2001296821 A1 AU2001296821 A1 AU 2001296821A1
Authority
AU
Australia
Prior art keywords
methods
inhibiting angiogenesis
oxidase inhibitors
nadph oxidase
nadph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296821A
Inventor
Ruhul Abid
William C. Aird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU2001296821A1 publication Critical patent/AU2001296821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU2001296821A 2000-10-12 2001-10-11 Methods of inhibiting angiogenesis using nadph oxidase inhibitors Abandoned AU2001296821A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23981800P 2000-10-12 2000-10-12
US60239818 2000-10-12
PCT/US2001/031856 WO2002030453A1 (en) 2000-10-12 2001-10-11 Methods of inhibiting angiogenesis using nadph oxidase inhibitors

Publications (1)

Publication Number Publication Date
AU2001296821A1 true AU2001296821A1 (en) 2002-04-22

Family

ID=22903874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296821A Abandoned AU2001296821A1 (en) 2000-10-12 2001-10-11 Methods of inhibiting angiogenesis using nadph oxidase inhibitors

Country Status (3)

Country Link
US (1) US20040001818A1 (en)
AU (1) AU2001296821A1 (en)
WO (1) WO2002030453A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603543A4 (en) * 2003-02-28 2009-03-04 Florey Howard Inst Therapeutic compositions
JP2007504122A (en) 2003-08-29 2007-03-01 ファイザー・インク Thienopyridine-phenylacetamide and its derivatives useful as novel anti-angiogenic agents
CN1890234A (en) 2003-12-23 2007-01-03 辉瑞大药厂 Novel quinoline derivatives
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
WO2006033965A2 (en) * 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US20100273854A1 (en) * 2007-06-15 2010-10-28 Hagar Kalinski Compositions and methods for inhibiting nadph oxidase expression
CA2702494A1 (en) 2007-10-19 2009-04-23 The Regents Of The University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
WO2010080452A2 (en) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS AND METHODS OF USE THEREOF
JP2012527231A (en) * 2009-05-20 2012-11-08 ユニヴァーシテ ド ジュネーヴ Inhibitors of mitochondrial activity of cancer initiating cells and use thereof
ES2372397B1 (en) * 2010-06-30 2012-11-26 Consejo Superior De Investigaciones Científicas (Csic) USE OF SOD-3 FOR ADJUVING IMMUNOTHERAPY AGAINST CANCER.
KR101189485B1 (en) 2011-11-22 2012-10-12 강원대학교산학협력단 A composition for diagnosing and treating cancer comprising nadph oxidase complex protein
CN103550193A (en) * 2013-06-05 2014-02-05 上海中医药大学附属岳阳中西医结合医院 Applications of acetovanillone and metabolic derivative thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01233228A (en) * 1988-03-11 1989-09-19 Toyo Jozo Co Ltd Metastasis preventive of malignant tumor cells
WO1994014950A1 (en) * 1992-12-28 1994-07-07 Sii Technoresearch, Inc. Human variant manganese superoxide dismutase
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
JPH07313180A (en) * 1994-05-19 1995-12-05 Mercian Corp Novel polyene compound
US5763496A (en) * 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
WO1999012539A1 (en) * 1997-09-10 1999-03-18 The Johns Hopkins University School Of Medicine The use of an nadph-oxidase inhibitor in the treatment of reperfusion injury

Also Published As

Publication number Publication date
WO2002030453A1 (en) 2002-04-18
US20040001818A1 (en) 2004-01-01

Similar Documents

Publication Publication Date Title
IL152753A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PL357995A1 (en) Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
IL160630A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL160648A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001228309A1 (en) N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
AU2001232036A1 (en) Pyrimidine derivatives as selective inhibitors of cox-2
MXPA03000694A (en) New use of lipase inhibitors.
AU2001288899A1 (en) Inhibitors of nadh:ubiquinone oxidoreductase
MXPA03000066A (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase.
AU2001296821A1 (en) Methods of inhibiting angiogenesis using nadph oxidase inhibitors
AU2001285750A1 (en) Urokinase inhibitors
AU2002216314A1 (en) Heterocyclic angiogenesis inhibitors
AU2001259990A1 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
AU7126900A (en) Enzyme inhibitors
AU2001252884A1 (en) Method of dopamine inhibition using l-threo-methylphenidate
AU2001245741A1 (en) Antisense inhibition of adam10 expression
GB0030284D0 (en) Enzyme inhibitors
AU2002214038A1 (en) Inhibitors of transglutaminases
AU7127000A (en) Enzyme inhibitors
AU7323000A (en) Conditional inhibition of vegetative propagation
AU2002218084A1 (en) Inhibitors of thromboxane formation and action
AU2001268853A1 (en) Biocatalyst inhibitors
AU7127100A (en) Enzyme inhibitors
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU1212002A (en) Use of lipase inhibitors